Not sure how bad downside is if bad. The company is cash flow positive when they are not doing clinical research. If results are bad they have extra cash lying around that they won't be using for commercialization of SFP so their balance sheet will look ok. What are annual sales? I think $40-50MM so not too bad. I think share price will recover organically over time. But are you willing to wait. Not sure.